No systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of registration
No systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of re-registration
No systemic daily treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of registration
Condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days of study drug administration; exceptions are:\r\n* Inhaled or topical steroids and\r\n* Adrenal replacement doses >  mg daily prednisone equivalents in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; however, systemic corticosteroids may be indicated after starting the study drugs to treat immune-related adverse reactions; inhaled or topical steroids and adrenal replacement doses > mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Participants with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study treatment administration
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids, and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
PHASE II EXCLUSION CRITERIA: Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids, and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring chronic systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients with contrast allergies who can tolerate contrast with corticosteroid premedication are not excluded
Patients who require systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg/day prednisone equivalent) or other immunosuppressive medications within  days of study administration. Inhaled or topical steroids and adrenal replacement doses >  mg/day prednisone equivalents are permitted in the absence of autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Participants with conditions requiring systemic treatment with either corticosteroids (> mg prednisone equivalents) or other immunosuppressive medications within  days of study treatment administration
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Current use of medications specified by the protocol as prohibited for administration in combination with study drug; this includes patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to the start of study drug; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Brief dosing for contrast allergy prophylaxis is allowed.
Condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with any condition or autoimmune disease that requires systemic corticosteroids (>  mg daily prednisone equivalents) or immunosuppressive medications within  days of study drug administration; inhaled or topical steroids are permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  day of study drug administration; inhaled, ocular, intraarticular, intranasal, and topical steroids are permitted
Patients who have a condition requiring systemic treatment with corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration are not eligible. However, inhaled or topical steroids, adrenal replacement doses, and >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Use of systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications <  days of registration\r\n* Note: inhaled or topical steroids are permitted; >  mg daily prednisone equivalents are permitted only in adrenal insufficiency in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily dexamethasone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Presence of condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone or equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
History of syndrome or medical condition(s) that requires systemic steroids (>  mg daily prednisone equivalents) or immunosuppressive medications.
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Require systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease
Known or suspected autoimmune disease; patients with a history of inflammatory bowel disease (including Crohns disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegeners granulomatosis) are excluded from this study; patients with a history of Hashimotos thyroiditis only requiring hormone replacement, type I diabetes, or psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed to participate; any condition requiring systemic treatment with corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to first dose of study drug; inhaled steroids and adrenal replacement steroids doses > mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses > mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients requiring systemic treatment with corticosteroids (greater than  mg prednisone equivalents) or immunosuppressive medications within  days of enrollment
Participants with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study treatment administration
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Known or suspected autoimmune disease; patients with a history of inflammatory bowel disease (including Crohns disease and ulcerative colitis) are excluded from this study as are patients with a history of autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegeners granulomatosis]) are excluded from this study; any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to first dose of study drug; inhaled steroids and adrenal replacement steroids doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (> mg daily of prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Subjects who require immunosuppressive medications such as methotrexate, tumor necrosis factor inhibitors, or systemic corticosteroids (> mg/day prednisone equivalents) within  weeks prior to study drug administration. Inhaled or topical steroids and adrenal replacement doses > mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Diagnosis of a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Use of systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications =<  days of registration; Note: Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients with a requirement for steroid treatment or other immunosuppressive treatment: patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Any condition requiring >  mg/d prednisone equivalents
Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications within  days of treatment
Subject is currently receiving or has received systemic corticosteroids =<  weeks prior to starting study drug or who have not fully recovered from side effects of such treatment; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to first dose of study drug; inhaled steroids and adrenal replacement steroids doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration.
Active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (>  mg daily of prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to study therapy administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
Have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to the first dose of study treatment (nivolumab). Inhaled or topical steroids and adrenal replacement doses (?  mg daily prednisone equivalents) are permitted in the absence of active autoimmune disease.
Patients will be excluded if they have a condition requiring systemic treatment with either corticosteroids (>mg/day prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > mg daily prednisone equivalents are permitted in the absence or active autoimmune disease.
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled, topical intranasal or intro-ocular steroids, and adrenal replacement doses <  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications within  day of study drug administration
Any condition requiring systemic treatment with corticosteroids (> mg daily Prednisone equivalents) or other immunosuppressive medications within  days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > mg daily Prednisone equivalents are permitted in the absence of active autoimmune disease
Patients who have a condition that requires systemic treatment with either corticosteroids within  days of enrollment (systemic corticosteroid therapy is defined as >  mg daily prednisone or its equivalent); or who require other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications within  days of treatment
Any syndrome that requires systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; of note: inhaled or topical steroids, and adrenal replacement doses >  mg daily prednisone equivalents, are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration should be excluded. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Concomitant medications\r\n** No systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of registration (inhaled steroids for patients with underlying chronic pulmonary disease is acceptable as long as they meet other eligibility as listed above)\r\n** No other planned concurrent investigational agents or other tumor directed therapy (chemotherapy, radiation) while on study
Presence of a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone or equivalents) or other immunosuppressive medications within  days of study drug administration; Note: Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease the absence of active autoimmune disease
Any condition requiring systemic treatment with corticosteroids (less than [>] mg daily prednisone equivalents) or other immunosuppressive medications within  before first dose of study drug. o Corticosteroids for topical use or in nasal spray are allowed, as are inhaled steroids and adrenal replacement steroid doses > mg daily in the absence of active autoimmune disease.